CUMBRE PHARMACEUTICALS INC has a total of 16 patent applications. Its first patent ever was published in 2005. It filed its patents most often in United States, EPO (European Patent Office) and Canada. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are MITOKININ INC, BENDER JOHN A and MISSION THERAPEUTICS LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 8 | |
#2 | EPO (European Patent Office) | 3 | |
#3 | Canada | 2 | |
#4 | China | 2 | |
#5 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Heterocyclic compounds | |
#3 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Ma Zhenkun | 13 |
#2 | Li Jing | 12 |
#3 | Ding Charles Z | 12 |
#4 | Kim In Ho | 11 |
#5 | Minor Keith P | 10 |
#6 | Harran Susan | 10 |
#7 | Jin Yafei | 8 |
#8 | Combrink Keith D | 7 |
#9 | He Yong | 6 |
#10 | Longgood Jamie C | 5 |
Publication | Filing date | Title |
---|---|---|
WO2009064792A1 | Quinolone carboxylic acid-substituted rifamycin derivatives | |
CN101031572A | (R/S) rifamycin derivatives, their preparation and pharmaceutical compositions | |
US2005277633A1 | Spiro-rifamycin derivatives targeting RNA polymerase | |
US2005256096A1 | C-25 carbamate rifamycin derivatives with activity against drug-resistant microbes | |
US2005203076A1 | Rifamycin C-11 oxime derivatives effective against drug-resistant microbes | |
US2005203085A1 | Rifamycin C-11 oxime cyclo derivatives effective against drug-resistant microbes | |
US2005209210A1 | Rifamycin imino derivatives effective against drug-resistant microbes | |
US2005261262A1 | Rifamycin derivatives effective against drug-resistant microbes |